Iodocyanopindolol (), also known as ICYP, is a synthetic compound derived from pindolol, primarily used as a radioligand in pharmacological research. It functions as a non-selective β-adrenoceptor antagonist and a serotonin 5-HT1A and 5-HT1B receptor antagonist. Its 125I-radiolabelled derivative, [125I]-iodocyanopindolol ([125I]-ICYP), is widely employed to map the distribution and density of β-adrenoceptors and serotonin receptors in tissues, particularly in the brain, heart, and other organs. Iodocyanopindolol is not used clinically but remains a critical tool in studying receptor pharmacolo
via PubMed
Iodocyanopindolol (), also known as ICYP, is a synthetic compound derived from pindolol, primarily used as a radioligand in pharmacological research. It functions as a non-selective β-adrenoceptor antagonist and a serotonin 5-HT1A and 5-HT1B receptor antagonist. Its 125I-radiolabelled derivative, [125I]-iodocyanopindolol ([125I]-ICYP), is widely employed to map the distribution and density of β-adrenoceptors and serotonin receptors in tissues, particularly in the brain, heart, and other organs. Iodocyanopindolol is not used clinically but remains a critical tool in studying receptor pharmacology and signal transduction. Its application extends to the central nervous system, where it labels 5-HT1B receptors in regions like the brainstem, hippocampus, and cortex, aiding research on serotonin autoreceptor regulation.
== Pharmacological properties == Iodocyanopindolol acts as a high-affinity antagonist at β1 and β2 adrenoceptors, with a lesser affinity for β3 adrenoceptors. It also antagonizes 5-HT1A and 5-HT1B serotonin receptors, making it a versatile radioligand for studying both adrenergic and serotonergic systems. The [125I]-ICYP form binds with high specificity, allowing quantitative analysis of receptor density (Bmax) and affinity (Kd) through techniques like autoradiography and radioligand binding assays.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).